Grifols, S.A. (GRFS) 10-Year Financial Performance & Capital Metrics

GRFS • • Industrial / General

HealthcareLarge PharmaPlasma & Biologics ManufacturersPlasma & Blood Products Specialists

AboutGrifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.Show more

Revenue $7.21B +9.4%
EBITDA $1.63B +32.6%
Net Income $157M +270.8%
EPS (Diluted) 0.23 +155.6%
Gross Margin 38.75% +2.8%
EBITDA Margin 22.6% +21.2%
Operating Margin 16.53% +39.3%
Net Margin 2.18% +238.9%
ROE 1.95% +256.3%
ROIC 5.01% +50.1%
Debt/Equity 1.17 -20.1%
Interest Coverage 1.54 +1.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak 3Y average ROE of 1.6%
✗Profits declining 24.2% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y7.95%

5Y7.18%

3Y13.5%

TTM7.31%

Profit (Net Income) CAGR

10Y-10.39%

5Y-24.15%

3Y-5.97%

TTM158.93%

EPS CAGR

10Y-10.4%

5Y-24.54%

3Y-5.2%

TTM162.61%

ROCE

10Y Avg7.67%

5Y Avg5.11%

3Y Avg4.96%

Latest6.29%

Peer Comparison

Plasma & Blood Products Specialists

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GRFSGrifols, S.A.	2.31B	8.93	38.83	9.41%	4.96%	4.94%	23.02%	1.17
OGNOrganon & Co.	2.26B	8.70	2.61	2.24%	7.95%	55.3%	26%	19.14

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.93B	4.05B	4.32B	4.49B	5.1B	5.34B	4.93B	6.06B	6.59B	7.21B
Revenue Growth %	0.17%	0.03%	0.07%	0.04%	0.14%	0.05%	-0.08%	0.23%	0.09%	0.09%
Cost of Goods Sold+	2B	2.14B	2.17B	2.44B	2.76B	3.08B	2.97B	3.85B	4.11B	4.42B
COGS % of Revenue	0.51%	0.53%	0.5%	0.54%	0.54%	0.58%	0.6%	0.63%	0.62%	0.61%
Gross Profit+	1.93B	1.91B	2.15B	2.05B	2.34B	2.26B	1.96B	2.21B	2.48B	2.79B
Gross Margin %	0.49%	0.47%	0.5%	0.46%	0.46%	0.42%	0.4%	0.37%	0.38%	0.39%
Gross Profit Growth %	0.14%	-0.01%	0.13%	-0.05%	0.14%	-0.04%	-0.13%	0.13%	0.12%	0.13%
Operating Expenses+	960.63M	972.88M	1.15B	1.06B	1.21B	1.26B	1.37B	1.43B	1.7B	1.6B
OpEx % of Revenue	0.24%	0.24%	0.27%	0.24%	0.24%	0.24%	0.28%	0.24%	0.26%	0.22%
Selling, General & Admin	736.43M	775.27M	860.35M	814.77M	942.82M	985.62M	1.06B	1.11B	1.27B	1.14B
SG&A % of Revenue	0.19%	0.19%	0.2%	0.18%	0.18%	0.18%	0.22%	0.18%	0.19%	0.16%
Research & Development	224.19M	197.62M	288.32M	240.66M	276.02M	294.22M	354.88M	361.14M	395.28M	384.04M
R&D % of Revenue	0.06%	0.05%	0.07%	0.05%	0.05%	0.06%	0.07%	0.06%	0.06%	0.05%
Other Operating Expenses	0	0	0	0	-8.97M	-20.8M	-48.86M	-37.66M	40.36M	74.48M
Operating Income+	970.37M	939.41M	1B	994.12M	1.13B	996.13M	595.06M	782.44M	782.32M	1.19B
Operating Margin %	0.25%	0.23%	0.23%	0.22%	0.22%	0.19%	0.12%	0.13%	0.12%	0.17%
Operating Income Growth %	0.13%	-0.03%	0.07%	-0.01%	0.14%	-0.12%	-0.4%	0.31%	-0%	0.52%
EBITDA+	1.16B	1.14B	1.22B	1.22B	1.43B	1.32B	954.83M	1.19B	1.23B	1.63B
EBITDA Margin %	0.29%	0.28%	0.28%	0.27%	0.28%	0.25%	0.19%	0.2%	0.19%	0.23%
EBITDA Growth %	0.11%	-0.02%	0.07%	0%	0.17%	-0.08%	-0.28%	0.25%	0.03%	0.33%
D&A (Non-Cash Add-back)	189.75M	201.87M	215.49M	228.61M	302.45M	321.53M	359.77M	410.98M	446.42M	437.9M
EBIT	914.86M	941.56M	945.25M	1B	1.14B	1.1B	584.27M	782.56M	723.08M	1.05B
Net Interest Income+	-234.49M	-234.9M	-253.67M	-279.28M	-228.77M	-275.44M	-222.26M	-410.68M	-453.63M	-725.1M
Interest Income	5.84M	9.93M	9.68M	13.99M	114.2M	9.14M	11.55M	33.86M	62.43M	48.05M
Interest Expense	224.61M	228.8M	249.53M	274.16M	324.38M	284.58M	233.81M	444.54M	516.06M	773.15M
Other Income/Expense	-280.12M	-226.66M	-307.62M	-268.28M	-314.26M	-117.5M	-244.61M	-444.42M	-575.3M	-748.02M
Pretax Income+	690.25M	712.75M	695.72M	725.84M	817.1M	878.63M	350.45M	338.01M	207.02M	444M
Pretax Margin %	0.18%	0.18%	0.16%	0.16%	0.16%	0.16%	0.07%	0.06%	0.03%	0.06%
Income Tax+	158.81M	168.21M	34.41M	131.44M	168.46M	169.64M	85.13M	90.11M	43.35M	231.19M
Effective Tax Rate %	0.77%	0.77%	0.95%	0.82%	0.77%	0.7%	0.54%	0.55%	0.2%	0.35%
Net Income+	532.14M	545.46M	662.7M	596.64M	625.15M	618.55M	188.73M	185.03M	42.32M	156.92M
Net Margin %	0.14%	0.13%	0.15%	0.13%	0.12%	0.12%	0.04%	0.03%	0.01%	0.02%
Net Income Growth %	0.13%	0.03%	0.21%	-0.1%	0.05%	-0.01%	-0.69%	-0.02%	-0.77%	2.71%
Net Income (Continuing)	531.44M	544.54M	661.31M	594.41M	648.64M	708.99M	265.33M	247.9M	163.67M	212.81M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	5.19M	6.5M	4.89M	471.05M	2.27B	1.61B	1.79B	2.33B	2.15B	2.72B
EPS (Diluted)+	0.78	0.80	0.97	0.87	0.94	0.73	0.27	0.31	0.09	0.23
EPS Growth %	0.13%	0.03%	0.21%	-0.1%	0.08%	-0.22%	-0.63%	0.15%	-0.71%	1.56%
EPS (Basic)	0.78	0.80	0.97	0.87	0.95	0.73	0.27	0.31	0.09	0.23
Diluted Shares Outstanding	685.66M	684.17M	684.24M	684.71M	663.69M	685.52M	681.56M	679.81M	679.76M	680.02M
Basic Shares Outstanding	685.28M	683.23M	684.2M	684.71M	659.98M	685.52M	681.56M	679.81M	679.76M	680.02M
Dividend Payout Ratio	0.42%	0.4%	0.33%	0.47%	0.38%	0.18%	1.34%	0%	-	0.01%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.09B	3.12B	2.95B	3.48B	6.02B	3.16B	5.51B	4.69B	6.13B	5.73B
Cash & Short-Term Investments	1.14B	895.01M	886.52M	1.03B	2.76B	590.51M	2.69B	580.24M	646.04M	1B
Cash Only	1.14B	895.01M	886.52M	1.03B	832.87M	579.65M	655.49M	549.21M	529.58M	979.78M
Short-Term Investments	0	0	0	0	1.93B	10.86M	2.03B	31.03M	116.47M	21.18M
Accounts Receivable	477.8M	528.52M	385.26M	401.57M	528.13M	383.23M	434.14M	774.2M	692.86M	1.08B
Days Sales Outstanding	44.32	47.63	32.57	32.67	37.81	26.19	32.12	46.6	38.36	54.62
Inventory	1.43B	1.64B	1.63B	1.95B	2.63B	2B	2.26B	3.24B	3.48B	3.56B
Days Inventory Outstanding	260.76	280.54	274.55	291.94	348.07	236.91	277.62	306.77	309.38	294.13
Other Current Assets	31.09M	48.32M	33.06M	63.1M	78.03M	172.88M	131.63M	80.88M	1.31B	78.58M
Total Non-Current Assets+	6.51B	7.01B	7.97B	8.99B	11.43B	12.11B	13.72B	16.54B	14.86B	15.68B
Property, Plant & Equipment	1.64B	1.81B	1.76B	1.95B	3.21B	3B	3.34B	4.28B	4.19B	4.31B
Fixed Asset Turnover	2.39x	2.24x	2.45x	2.30x	1.59x	1.78x	1.48x	1.42x	1.57x	1.67x
Goodwill	3.53B	3.64B	4.59B	5.21B	6.18B	5.33B	6.23B	7.01B	6.8B	7.4B
Intangible Assets	1.16B	1.2B	1.27B	1.39B	1.61B	1.56B	1B	2.95B	1.21B	2.93B
Long-Term Investments	78.08M	232.42M	259.06M	228.82M	278.35M	2.07B	2.27B	1.99B	451.9M	528.97M
Other Non-Current Assets	29.03M	58.47M	29.84M	105.69M	6.1M	0	882.61M	124.19M	2.21B	167.72M
Total Assets+	9.6B	10.13B	10.92B	12.48B	17.45B	15.27B	19.23B	21.23B	20.99B	21.41B
Asset Turnover	0.41x	0.40x	0.40x	0.36x	0.29x	0.35x	0.26x	0.29x	0.31x	0.34x
Asset Growth %	0.14%	0.05%	0.08%	0.14%	0.4%	-0.12%	0.26%	0.1%	-0.01%	0.02%
Total Current Liabilities+	1.05B	1.07B	977.99M	1.26B	1.53B	1.34B	3.47B	2.02B	2.33B	2.16B
Accounts Payable	409.99M	461.07M	423.1M	561.88M	653.16M	601.62M	628.99M	787.96M	822.95M	852.3M
Days Payables Outstanding	74.69	78.73	71.3	84.15	86.46	71.18	77.29	74.7	73.11	70.42
Short-Term Debt	181.14M	200.09M	129.12M	7.08M	358.69M	276.93M	2.35B	578.92M	916.51M	523.13M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	0	1000K	0	1000K
Other Current Liabilities	199.19M	115.71M	275.65M	507.75M	294.78M	264.51M	119.44M	381.59M	108.6M	81.95M
Current Ratio	2.93x	2.91x	3.01x	2.77x	3.92x	2.37x	1.59x	2.32x	2.64x	2.66x
Quick Ratio	1.57x	1.38x	1.35x	1.22x	2.21x	0.87x	0.94x	0.72x	1.14x	1.01x
Cash Conversion Cycle	230.4	249.44	235.82	240.46	299.42	191.92	232.45	278.67	274.63	278.34
Total Non-Current Liabilities+	5.25B	5.33B	6.31B	6.52B	8.22B	7.22B	8.44B	11.23B	11.15B	10.64B
Long-Term Debt	4.57B	4.68B	5.87B	6.01B	6.84B	5.9B	6.94B	8.15B	8.99B	8.42B
Capital Lease Obligations	5.85M	6.09M	5.42M	9.54M	781.58M	690.86M	825.16M	914.59M	1B	1.02B
Deferred Tax Liabilities	631.57M	600.65M	388.91M	404.4M	520.65M	556.81M	0	1.03B	0	1.01B
Other Non-Current Liabilities	30.79M	36.09M	29.4M	86.37M	77.45M	53.93M	675.34M	1.12B	1.16B	170.46M
Total Liabilities	6.3B	6.4B	7.29B	7.78B	9.75B	8.55B	11.92B	13.25B	13.48B	12.8B
Total Debt+	4.76B	4.89B	6.01B	6.03B	7.98B	6.91B	10.17B	9.75B	11.02B	10.09B
Net Debt	3.62B	3.99B	5.12B	5B	7.14B	6.33B	9.51B	9.2B	10.49B	9.11B
Debt / Equity	1.44x	1.31x	1.65x	1.28x	1.04x	1.03x	1.39x	1.22x	1.47x	1.17x
Debt / EBITDA	4.10x	4.28x	4.93x	4.93x	5.56x	5.25x	10.65x	8.17x	8.97x	6.19x
Net Debt / EBITDA	3.12x	3.50x	4.20x	4.09x	4.98x	4.81x	9.96x	7.71x	8.53x	5.59x
Interest Coverage	4.32x	4.11x	4.02x	3.63x	3.49x	3.50x	2.55x	1.76x	1.52x	1.54x
Total Equity+	3.3B	3.73B	3.63B	4.7B	7.68B	6.72B	7.32B	7.98B	7.51B	8.61B
Equity Growth %	0.24%	0.13%	-0.03%	0.29%	0.64%	-0.13%	0.09%	0.09%	-0.06%	0.15%
Book Value per Share	4.81	5.45	5.31	6.86	11.58	9.80	10.74	11.73	11.05	12.66
Total Shareholders' Equity	3.3B	3.72B	3.63B	4.23B	5.41B	5.11B	5.52B	5.65B	5.37B	5.88B
Common Stock	1.03B	1.03B	1.03B	1.03B	134.26M	119.6M	119.6M	119.6M	119.6M	119.6M
Retained Earnings	412.53M	422.55M	539.71M	459.89M	0	618.55M	248M	0	79.36M	156.92M
Treasury Stock	-58.58M	-68.71M	-62.42M	-55.44M	-55.66M	-43.73M	-164.19M	-162.22M	-152.75M	-134.45M
Accumulated OCI	1.91B	2.34B	2.12B	2.79B	4.31B	3.5B	4.41B	4.78B	4.41B	4.83B
Minority Interest	5.19M	6.5M	4.89M	471.05M	2.27B	1.61B	1.79B	2.33B	2.15B	2.72B

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	742.78M	553.28M	841.75M	737.43M	568.93M	1.11B	596.98M	-10.87M	218.69M	902.17M
Operating CF Margin %	0.19%	0.14%	0.19%	0.16%	0.11%	0.21%	0.12%	-0%	0.03%	0.13%
Operating CF Growth %	-0.24%	-0.26%	0.52%	-0.12%	-0.23%	0.95%	-0.46%	-1.02%	21.12%	3.13%
Net Income	690.25M	712.75M	695.72M	725.84M	817.1M	618.55M	188.73M	361.26M	207.02M	444M
Depreciation & Amortization	189.75M	201.87M	215.49M	228.61M	302.45M	321.53M	359.77M	407.86M	446.42M	437.9M
Stock-Based Compensation	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-60.17M	-197.02M	-3.67M	-104.38M	-69.09M	61.66M	229.84M	-170.77M	-71.91M	-2.1M
Working Capital Changes	-77.06M	-164.32M	-65.8M	-112.64M	-481.54M	108.6M	-181.35M	-609.22M	-362.84M	22.38M
Change in Receivables	144.41M	-25.18M	80.11M	-13.14M	-99.37M	-35.43M	-16.81M	-80.17M	-68.81M	-41.88M
Change in Inventory	-120.64M	-173M	-165.51M	-231.67M	-323.75M	164.63M	-157.47M	-600.25M	-411.44M	25.82M
Change in Payables	-95.26M	36.47M	22.29M	135.26M	0	0	0	80.21M	0	0
Cash from Investing+	-633.11M	-506.65M	-2.19B	-781.87M	-548.79M	-858.12M	-854.15M	-1.98B	-394.72M	886.67M
Capital Expenditures	-567.02M	-292.69M	-322.97M	-307.72M	-310.38M	-280.15M	-247.37M	-375.56M	-224.44M	-232.54M
CapEx % of Revenue	0.14%	0.07%	0.07%	0.07%	0.06%	0.05%	0.05%	0.06%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-30.13M	-40.85M	762K	550K	-99.21M	-109.37M	-87.65M	3.28M	-62.63M	1.45B
Cash from Financing+	-158.04M	-329.56M	1.43B	152.5M	-332.36M	-354.4M	2.3B	-173.49M	171.49M	-1.36B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-221.77M	-216.15M	-218.26M	-278.84M	-238.74M	-113.23M	-252.44M	-592K	0	-962K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	17.09M	-21.49M	-156.45M	390.87M	-19.83M	2.2M	-70.56M	-65.16M	287.89M	-1.25B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	175.76M	260.59M	518.77M	429.71M	156.63M	830.18M	349.6M	-386.43M	-91.63M	530.8M
FCF Margin %	0.04%	0.06%	0.12%	0.1%	0.03%	0.16%	0.07%	-0.06%	-0.01%	0.07%
FCF Growth %	-0.75%	0.48%	0.99%	-0.17%	-0.64%	4.3%	-0.58%	-2.11%	0.76%	6.79%
FCF per Share	0.26	0.38	0.76	0.63	0.24	1.21	0.51	-0.57	-0.13	0.78
FCF Conversion (FCF/Net Income)	1.40x	1.01x	1.27x	1.24x	0.91x	1.80x	3.16x	-0.06x	5.17x	5.75x
Interest Paid	0	0	0	0	0	155.79M	155.12M	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	17.84%	15.52%	18%	14.32%	10.1%	8.59%	2.69%	2.42%	0.55%	1.95%
Return on Invested Capital (ROIC)	11.43%	9.63%	9.13%	8.08%	6.92%	5.36%	2.99%	3.45%	3.34%	5.01%
Gross Margin	49.08%	47.22%	49.84%	45.68%	45.92%	42.23%	39.78%	36.51%	37.67%	38.75%
Net Margin	13.52%	13.47%	15.35%	13.3%	12.26%	11.58%	3.83%	3.05%	0.64%	2.18%
Debt / Equity	1.44x	1.31x	1.65x	1.28x	1.04x	1.03x	1.39x	1.22x	1.47x	1.17x
Interest Coverage	4.32x	4.11x	4.02x	3.63x	3.49x	3.50x	2.55x	1.76x	1.52x	1.54x
FCF Conversion	1.40x	1.01x	1.27x	1.24x	0.91x	1.80x	3.16x	-0.06x	5.17x	5.75x
Revenue Growth	17.26%	2.93%	6.62%	3.91%	13.64%	4.73%	-7.62%	22.92%	8.71%	9.41%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023
Haemoderivatives	-	3.52B	3.99B	4.24B	3.81B	5.01B	5.56B
Haemoderivatives Growth	-	-	13.56%	6.24%	-10.08%	31.20%	11.05%
Transfusional medicine	-	-	-	-	712.24M	640.6M	648.48M
Transfusional medicine Growth	-	-	-	-	-	-10.06%	1.23%
Other Product	-	-	-	-	39.62M	250.16M	203.45M
Other Product Growth	-	-	-	-	-	531.41%	-18.67%
Bio supplies	-	-	-	-	225.76M	146.08M	159.96M
Bio supplies Growth	-	-	-	-	-	-35.30%	9.50%
Other diagnostic	-	-	-	-	23.63M	21.74M	21.79M
Other diagnostic Growth	-	-	-	-	-	-7.98%	0.23%
Hospital supplies	-	-	-	-	70.22M	-	-
Hospital supplies Growth	-	-	-	-	-	-	-
Fluid therapy and nutrition	-	-	-	-	46.67M	-	-
Fluid therapy and nutrition Growth	-	-	-	-	-	-	-
Transfusional Medicine	-	650.18M	680.77M	714.16M	-	-	-
Transfusional Medicine Growth	-	-	4.70%	4.91%	-	-	-
Bio Supplies Product	-	167M	266.54M	224.09M	-	-	-
Bio Supplies Product Growth	-	-	59.60%	-15.93%	-	-	-
Hospital Supplies	-	58.01M	67.49M	58.3M	-	-	-
Hospital Supplies Growth	-	-	16.33%	-13.61%	-	-	-
Fluid Therapy And Nutrition	-	52.57M	47.68M	41.36M	-	-	-
Fluid Therapy And Nutrition Growth	-	-	-9.31%	-13.25%	-	-	-
Others Product	-	22.45M	22.82M	31.99M	-	-	-
Others Product Growth	-	-	1.64%	40.18%	-	-	-
Other Diagnostic	-	19.8M	19.94M	27.63M	-	-	-
Other Diagnostic Growth	-	-	0.71%	38.59%	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023
USA and Canada	-	-	-	-	3.15B	3.86B	3.9B
USA and Canada Growth	-	-	-	-	-	22.22%	1.12%
the world	-	-	-	-	872.12M	1.18B	1.44B
the world Growth	-	-	-	-	-	34.86%	22.19%
European Union	-	-	-	-	544.04M	711.58M	893.05M
European Union Growth	-	-	-	-	-	30.79%	25.50%
Spain	-	-	-	-	362.41M	320.63M	362.88M
Spain Growth	-	-	-	-	-	-11.53%	13.18%
United States And Canada	2.9B	2.97B	3.39B	3.6B	-	-	-
United States And Canada Growth	-	2.69%	14.00%	6.16%	-	-	-
Rest Of World	734.59M	712.02M	851.22M	905.8M	-	-	-
Rest Of World Growth	-	-3.07%	19.55%	6.41%	-	-	-
European Union Excluding Spain	444.09M	535.36M	588.38M	495.32M	-	-	-
European Union Excluding Spain Growth	-	20.55%	9.90%	-15.82%	-	-	-
Country Of Domicile	242.89M	264.91M	268.29M	339.17M	-	-	-
Country Of Domicile Growth	-	9.07%	1.27%	26.42%	-	-	-

Frequently Asked Questions

Valuation & Price

Grifols, S.A. (GRFS) has a price-to-earnings (P/E) ratio of 38.8x. This suggests investors expect higher future growth.

Growth & Financials

Grifols, S.A. (GRFS) reported $7.52B in revenue for fiscal year 2024. This represents a 319% increase from $1.80B in 2011.

Grifols, S.A. (GRFS) grew revenue by 9.4% over the past year. This is steady growth.

Yes, Grifols, S.A. (GRFS) is profitable, generating $372.7M in net income for fiscal year 2024 (2.2% net margin).

Dividend & Returns

Grifols, S.A. (GRFS) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.

Grifols, S.A. (GRFS) has a return on equity (ROE) of 1.9%. This is below average, suggesting room for improvement.

Grifols, S.A. (GRFS) generated $851.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...